암 생검 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 유형별, 용도별, 지역별, 부문별 예측(2024-2030년)

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,176,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,550,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,299,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

암 생검 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 암 생검 시장 규모는 2030년까지 516억 1,000만 달러에 달하며, 2024-2030년 CAGR은 8.11%를 기록할 것으로 예측됩니다.

분자 의학의 발전으로 암의 분자 특성 분석을 위한 새로운 장비의 개발이 용이해졌습니다. 그 결과, 액체생검의 수용과 승인 증가는 전체 시장 성장의 큰 원동력이 될 것으로 예상됩니다.

많은 신흥 제조업체들이 내시경 기반 암 생검을 개선할 수 있는 장비 개발에 전념하고 있습니다. 예를 들어 2023년 3월 스웨덴의 BiBBInstruments AB는 EndoDrill이라는 브랜드로 암 생검 시장에서 확고한 입지를 구축했습니다. 이 회사는 기존 생검기구와 관련하여 암 환자의 신속하고 정확한 진단을 가능하게 하는 생검기구를 변경했습니다. 또한 코어니들 및 연성 내시경 생검에 대응하는 생검기구를 제공합니다. 이러한 신흥 국가 시장을 개척하고 있는 기업은 암 생검 기구의 접근성을 높일 것으로 예상됩니다.

종양학 기반 유전체 데이터 분석 및 맞춤형 의료 분야는 액체생검의 등장으로 유리한 전망을 보일 것으로 예상됩니다. 규제 당국은 액체생검이 가진 큰 잠재력으로 인해 이들 제품의 상용화를 적극적으로 지원하며 임상 현장에서의 활용을 촉진하고 있습니다. 액체생검은 다양한 체액을 통해 암을 쉽게 검출할 수 있으며, 이 기술의 발전으로 진단을 위한 암 생체 물질을 얻기 위한 매력적인 비침습적 접근법이 되고 있습니다.

리퀴드 바이오옵시 분야는 바이오의약품 제조 및 유전체 데이터 분석 관련 기업의 대규모 투자와 전략적 노력으로 인해 향후 수년간 빠르게 성장할 것으로 예상됩니다. 신생 기업은 QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, SOPHiA Genetics와 같은 기존 업계 참여 기업과 파트너십을 맺는 경향이 강합니다. 이러한 공동 연구 동향은 전체 시장의 성장을 더욱 촉진할 것으로 예상됩니다.

암 생검 시장 보고서 하이라이트

• 2023년에는 키트 및 소모품이 제품별로 가장 큰 시장 점유율을 차지할 것으로 예상되며, 이러한 우위는 예측 기간 중 지속될 것으로 예상됩니다. 키트 및 소모품의 채택 증가는 종양 생검에서 액체생검으로의 눈에 띄는 전환에 기인합니다.
• 조직 생검은 여전히 생검 과정의 기본이며 다양한 진단 용도로 널리 사용되고 있습니다. 또한 종양 생검은 주로 개인 수준의 진단 및 진행중인 종양 치료의 효과를 모니터링하는 데 주로 사용됩니다.
• 용도별로는 유방암이 2023년 세계 시장을 장악할 것으로 예상되며, 예측 기간 중에도 선두를 유지할 것으로 예상됩니다. 개복 수술 생검은 이러한 질환의 진단에 있으며, 확립된 정확성으로 인해 의심스러운 유방 병변이 있는 환자를 평가하기 위한 기준으로 여전히 사용되고 있습니다. 따라서 이 부문의 매출은 유방 병변 진단에 대한 입증된 효과로 인해 강화되고 있습니다.
• 북미는 활동적인 조직과 암 재단이 집중되어 있으며, 2023년 가장 큰 매출 점유율을 차지했습니다. 미국의 정부 조직과 민간암 재단의 강력한 네트워크는 이 지역의 매출 창출 능력에 크게 기여하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 암 생검 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 암 생검 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 암 생검 시장 : 제품 추정·동향 분석

• 세계의 암 생검 시장 : 제품 대시보드
• 세계의 암 생검 시장 : 제품 변동 분석
• 제품별, 매출
• 기기
• 키트와 소모품
• 서비스

제5장 암 생검 시장 : 유형 추정·동향 분석

• 세계의 암 생검 시장 : 유형 대시보드
• 세계의 암 생검 시장 : 유형 변동 분석
• 유형별, 매출
• 조직 생검
• 액체생검
• 기타

제6장 암 생검 시장 : 용도 추정·동향 분석

• 세계의 암 생검 시장 : 용도 대시보드
• 세계의 암 생검 시장 : 용도 변동 분석
• 용도별, 매출별
• 유방암
• 대장암
• 자궁경부암
• 폐암
• 전립선암
• 피부암
• 혈액암
• 신장암
• 간암
• 췌장암
• 난소암
• 기타

제7장 암 생검 시장 : 유형, 제품, 용도, 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2023
  • QIAGEN
  • Illumina, Inc.
  • ANGLE plc
  • BD(Becton, Dickinson and Company)
  • Myriad Genetics, Inc.
  • Hologic, Inc.
  • Biocept, Inc.
  • Thermo Fisher Scientific, Inc.
  • Danaher
  • F. Hoffmann-La Roche Ltd.
  • Lucence Health Inc.
  • GRAIL, Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • Biodesix(Integrated Diagnostics)
  • Oncimmune
  • Epigenomics AG
  • HelioHealth(Laboratory for Advanced Medicine)
  • Genesystems, Inc.(Genesys Biolabs)
  • Chronix Biomedical, Inc.
  • Personal Genome Diagnostics Inc.
  • Natera, Inc.
  • Personalis Inc.

KSA

영문 목차

영문목차

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

• In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
• Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
• In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
• North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and type outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advent of liquid biopsy
    • 3.2.1.2. Transition of novel oncology diagnostics from bench to clinics
    • 3.2.1.3. Advancements in quality and payment pertaining to genetic cancer tests
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risks associated with biopsy procedures
    • 3.2.2.2. Technical and clinical challenges
• 3.3. Cancer Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cancer Biopsy Market: Product Estimates & Trend Analysis

• 4.1. Global Cancer Biopsy Market: Product Dashboard
• 4.2. Global Cancer Biopsy Market: Product Movement Analysis
• 4.3. Global Cancer Biopsy Market by Product, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Kits and Consumables
  • 4.5.1. Kits and consumables market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Cancer Biopsy Market: Type Estimates & Trend Analysis

• 5.1. Global Cancer Biopsy Market: Type Dashboard
• 5.2. Global Cancer Biopsy Market: Type Movement Analysis
• 5.3. Global Cancer Biopsy Market by Type, Revenue
• 5.4. Tissue Biopsies
  • 5.4.1. Tissue biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Needle Biopsies
  • 5.4.3. Needle biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Fine Needle Aspiration (FNA)
    • 5.4.4.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Core Needle Biopsy (CNB)
    • 5.4.5.1. Core Needle Biopsy (CNB) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. Surgical Biopsies
  • 5.4.7. Surgical biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Liquid Biopsies
  • 5.5.1. Liquid biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Cancer Biopsy Market: Application Estimates & Trend Analysis

• 6.1. Global Cancer Biopsy Market: Application Dashboard
• 6.2. Global Cancer Biopsy Market: Application Movement Analysis
• 6.3. Global Cancer Biopsy Market by Application, Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Colorectal Cancer
  • 6.5.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Cervical Cancer
  • 6.6.1. Cervical cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Lung Cancer
  • 6.7.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Prostate Cancer
  • 6.8.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. Skin Cancer
  • 6.9.1. Skin cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.10. Blood Cancer
  • 6.10.1. Blood cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.11. Kidney Cancer
  • 6.11.1. Kidney cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.12. Liver Cancer
  • 6.12.1. Liver cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.13. Pancreatic Cancer
  • 6.13.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.14. Ovarian Cancer
  • 6.14.1. Ovarian cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.15. Others
  • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. QIAGEN
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Illumina, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. ANGLE plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BD (Becton, Dickinson and Company)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Myriad Genetics, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Hologic, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Biocept, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Thermo Fisher Scientific, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danaher
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. F. Hoffmann-La Roche Ltd.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Lucence Health Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. GRAIL, Inc.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives
  • 8.3.16. Guardant Health Inc.
    • 8.3.16.1. Company overview
    • 8.3.16.2. Financial performance
    • 8.3.16.3. Product benchmarking
    • 8.3.16.4. Strategic initiatives
  • 8.3.17. Exact Sciences Corporation
    • 8.3.17.1. Company overview
    • 8.3.17.2. Financial performance
    • 8.3.17.3. Product benchmarking
    • 8.3.17.4. Strategic initiatives
  • 8.3.18. Freenome Holdings, Inc.
    • 8.3.18.1. Company overview
    • 8.3.18.2. Financial performance
    • 8.3.18.3. Product benchmarking
    • 8.3.18.4. Strategic initiatives
  • 8.3.19. Biodesix (Integrated Diagnostics)
    • 8.3.19.1. Company overview
    • 8.3.19.2. Financial performance
    • 8.3.19.3. Product benchmarking
    • 8.3.19.4. Strategic initiatives
  • 8.3.20. Oncimmune
    • 8.3.20.1. Company overview
    • 8.3.20.2. Financial performance
    • 8.3.20.3. Product benchmarking
    • 8.3.20.4. Strategic initiatives
  • 8.3.21. Epigenomics AG
    • 8.3.21.1. Company overview
    • 8.3.21.2. Financial performance
    • 8.3.21.3. Product benchmarking
    • 8.3.21.4. Strategic initiatives
  • 8.3.22. HelioHealth (Laboratory for Advanced Medicine)
    • 8.3.22.1. Company overview
    • 8.3.22.2. Financial performance
    • 8.3.22.3. Product benchmarking
    • 8.3.22.4. Strategic initiatives
  • 8.3.23. Genesystems, Inc. (Genesys Biolabs)
    • 8.3.23.1. Company overview
    • 8.3.23.2. Financial performance
    • 8.3.23.3. Product benchmarking
    • 8.3.23.4. Strategic initiatives
  • 8.3.24. Chronix Biomedical, Inc.
    • 8.3.24.1. Company overview
    • 8.3.24.2. Financial performance
    • 8.3.24.3. Product benchmarking
    • 8.3.24.4. Strategic initiatives
  • 8.3.25. Personal Genome Diagnostics Inc.
    • 8.3.25.1. Company overview
    • 8.3.25.2. Financial performance
    • 8.3.25.3. Product benchmarking
    • 8.3.25.4. Strategic initiatives
  • 8.3.26. Natera, Inc.
    • 8.3.26.1. Company overview
    • 8.3.26.2. Financial performance
    • 8.3.26.3. Product benchmarking
    • 8.3.26.4. Strategic initiatives
  • 8.3.27. Personalis Inc.
    • 8.3.27.1. Company overview
    • 8.3.27.2. Financial performance
    • 8.3.27.3. Product benchmarking
    • 8.3.27.4. Strategic initiatives

관련자료